The makers of the antipsychotic drug Risperdal, Janssen Pharmaceuticals and Johnson & Johnson, face ongoing issues with the drug and the company recently settled several claims shortly before the lawsuits were set to go to trial. Young male users of Risperdal claim the drug caused them to develop a condition known as gynecomastia (development of […]
Risperdal
Johnson & Johnson has long been one of the most respected companies in the health and personal care industries. It all began in 1886, when the Johnson brothers founded the company in New Jersey. The Johnson family’s intention was to make products that put consumer safety first, while making the world a better place. They […]
Users of the drug Risperdal and members of the medical community continue to voice their concern over the antipsychotic medication manufactured by Ortho-McNeil-Janssen Pharmaceutical and Johnson & Johnson. The drug was originally approved by the FDA in 1993 for the short-term treatment of schizophrenia in adults, and later received approval for treating autism-related behaviors and […]
Risperidal was the world’s first medication approved for treating autism in children, and it’s still the most widely prescribed. Upon initial release, it seemed like a miracle drug. Unquestionably, it effectively manages many of the behavioral difficulties associated with autism. The drug is also used in the treatment of schizophrenia and bipolar disorder. But for […]
Johnson & Johnson subsidiary Janssen Pharmaceuticals, Inc., maker of the drug risperidone (Risperdal), which has been linked to male breast development, faces a new lawsuit in a New York District Court alleging that Risperdal caused a 21 year old man to undergo multiple surgeries that resulted in severe pain, injury and emotional suffering. Shaquil Bird […]
In response to the concerns over the link between Risperdal and Gynecomastia in minors, Andrus Wagstaff PC is investigating potential lawsuits for victims. The U.S. Food and Drug Administration in 2007 approved Risperdal (Risperdone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of […]
